Hoersholm; February 17, 2016 – Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI, in collaboration with Aarhus University Hospital, in the online journal PLOS ONE publishes positive results of a clinical test of its Drug Response Predictor (DRP(TM)) technology in patients with gastroesophageal cancer.
Based on a pre-treatment biopsy, the DRP(TM) was able to correctly predict retrospectively which patients would benefit from standard chemotherapy. “The miRNA profile predictive for sensitivity to cisplatin, epirubicine and capecitabine was shown to be independently associated with overall survival and disease-specific survival in patients with gastro-esophageal cancer,” the conclusion reads.
“This is a further validation of the Drug Response Predictor – DRP(TM)- technology, building on microRNA, which was recently granted a patent in Australia. We are diligently building on strengthening data for the clinical relevance of the DRP(TM) for the use in personalized medicine,” Said Adjunct professor Peter Buhl Jensen, MD, PhD and CEO of MPI.
Link to the publication: http://dx.plos.org/10.1371/journal.pone.0148070
About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM)
MPI’s lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patients’ gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. This DRP(TM) method builds on the comparison of sensitive and resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. MicroRNA is used on certain products whereas the messenger RNA is more broadly useable and more validated. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.
For further information, please contact
CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD
Phone: +45 21 60 89 22
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark